Sonal, Swati
Deshpande, Vikram
Ting, David T.
Cusack, James C.
Parikh, Aparna R.
Neyaz, Azfar
Pankaj, Amaya
Taylor, Martin S.
Dinaux, Anne M.
Leijssen, Lieve G. J.
Boudreau, Chloe
Locascio, Joseph J.
Kunitake, Hiroko
Goldstone, Robert N.
Bordeianou, Liliana G.
Cauley, Christy E.
Ricciardi, Rocco
Berger, David L. http://orcid.org/0000-0002-0328-4235
Article History
Received: 22 March 2022
Accepted: 27 June 2022
First Online: 2 August 2022
Disclosures
: D.T.T. has received consulting fees from ROME Therapeutics, Tekla Capital, Ikena Oncology, Foundation Medicine, Inc., NanoString Technologies, EMD Millipore Sigma, and Pfizer that are not related to this work. D.T.T. is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc., which is not related to this work. D.T.T. receives research support from ACD-Biotechne, PureTech Health LLC, and Ribon Therapeutics, which was not used in this work. D.T.T.’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. A.P.—Equity in C2i genomics and, in the last 36 months, has served as an advisor/consultant for Eli Lilly, Pfizer, Inivata, Biofidelity, Natera, Checkmate Pharmaceuticals and Guardant. She has been on the DSMC for a Roche study and has received research funding to the Institution from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, BMS, Mirati, Novartis, Genentech, Natera, and Daiichi Sankyo. M.T.—ROME Therapeutics, consulting fees and equity.